A novel method for quantitative measurement of a biomarker in the presence of a therapeutic monoclonal antibody directed against the biomarker

被引：12

作者：

Davis, R. Aleks ^{[1
]}

Butterfield, Anthony M. ^{[1
]}

Konrad, Robert J. ^{[1
]}

Bourdage, James S. ^{[1
]}

机构：

[1] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA

来源：

JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS | 2008年 / 48卷 / 03期

关键词：

Enzyme immunoassay; Biomarker; Monoclonal antibody; ELISA; Antibody interference;

D O I：

10.1016/j.jpba.2008.07.012

中图分类号：

O65 [分析化学];

学科分类号：

070302 [分析化学]; 081704 [应用化学];

摘要：

Therapeutic monoclonal antibodies (MoAb) have become important tools in the treatment of numerous diseases. Many of these MoAb are present in the blood at very high levels due to high dosing and long half-lives. Quantification of biomarkers bound by these therapeutic MoAb can be an important factor in determining efficacy and dosing requirements. However, quantitation of these biomarkers with reasonable accuracy can be very difficult to accomplish due to concomitant binding of the therapeutic MoAb. We describe here a novel method for quantifying total (free plus bound) biomarker concentration in the presence of high levels of therapeutic MoAb using a single non-competing MoAb in a capture/elution format. This assay has the capability to accurately detect and quantitate circulating ng/ml biomarker levels in the presence of 200 mu g/ml or more of therapeutic MoAb. (c) 2008 Elsevier B.V. All rights reserved.

引用

页码：897 / 901

页数：5

共 12 条

[1]

Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework [J].

Atkinson, AJ ;

Colburn, WA ;

DeGruttola, VG ;

DeMets, DL ;

Downing, GJ ;

Hoth, DF ;

Oates, JA ;

Peck, CC ;

Schooley, RT ;

Spilker, BA ;

Woodcock, J ;

Zeger, SL .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (03) :89-95

[2]

An affinity capture elution (ACE) assay for detection of anti-drug antibody to monoclonal antibody therapeutics in the presence of high levels of drug [J].

Bourdage, James S. ;

Cook, Carolyn A. ;

Farrington, Daphne L. ;

Chain, Jana S. ;

Konrad, Robert J. .

JOURNAL OF IMMUNOLOGICAL METHODS, 2007, 327 (1-2) :10-17

[3]

Effect of double antigen bridging immunoassay format on antigen coating concentration dependence and implications for designing immunogenicity assays for monoclonal antibodies [J].

Bourdage, JS ;

Lee, TN ;

Taylor, JM ;

Willey, MB ;

Brandt, JT ;

Konrad, RJ .

JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2005, 39 (3-4) :685-690

[4]

Active and passive immunotherapy for Neurodegenerative disorders [J].

Brody, David L. ;

Holtzman, David M. .

ANNUAL REVIEW OF NEUROSCIENCE, 2008, 31 :175-193

[5]

Comparison of cardiac troponin I immunoassays variably affected by circulating autoantibodies [J].

Eriksson, S ;

Ilva, T ;

Becker, C ;

Lund, J ;

Porela, P ;

Pulkki, K ;

Voipio-Pulkki, LM ;

Pettersson, K .

CLINICAL CHEMISTRY, 2005, 51 (05) :848-855

[6]

Key elements of bioanalytical method validation for macromolecules [J].

Kelley, Marian ;

DeSilva, Binodh .

AAPS JOURNAL, 2007, 9 (02) :E156-E163

[7]

Towards a better understanding of heterophile (and the like) antibody interference with modem immunoassays [J].

Levinson, SS ;

Miller, JJ .

CLINICA CHIMICA ACTA, 2002, 325 (1-2) :1-15

[8]

MALONEY DG, 1994, BLOOD, V84, P2457

[9]

Protein biomarker discovery and validation: the long and uncertain path to clinical utility [J].

Rifai, Nader ;

Gillette, Michael A. ;

Carr, Steven A. .

NATURE BIOTECHNOLOGY, 2006, 24 (08) :971-983

[10]

Detection of antibodies against therapeutic proteins in the presence of residual therapeutic protein using a solid-phase extraction with acid dissociation (SPEAD) sample treatment prior to ELISA [J].

Smith, Holly W. ;

Butterfield, Anthony ;

Sun, Deqin .

REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2007, 49 (03) :230-237

← 1 2 →